Nanocopoeia
Nanocopoeia, a pharmaceutical company, excels in enhancing drug performance through advanced delivery technology.
Founded
2001Nanocopoeia, a pharmaceutical company, excels in enhancing drug performance through advanced delivery technology.
Founded in 2001 through a technology license with the University of Minnesota, Nanocopoeia is a privately held pharmaceutical company based in St. Paul, MN. The company specializes in solving high-value, high-barrier drug product issues, particularly those related to insolubility and bioavailability. Nanocopoeia's core mission is to enhance drug performance through advanced delivery technology, focusing on generating macro-particles for oral-solid drug development. Their market focus includes pharmaceutical companies looking to improve the efficacy of low-solubility drugs.
Nanocopoeia has demonstrated strong proof-of-concept in enhancing low solubility drug performance and has made solid progress across its target drug pipeline. Notable affiliated individuals include researchers and technologists from the University of Minnesota. The company has achieved significant milestones in scaling up its technology and has had a substantial impact on the pharmaceutical industry by addressing critical challenges in drug delivery.
Companies similar to Nanocopoeia include Lypro Biosciences, Nanomedex Pharmaceuticals, Nano PharmaSolutions and MAA Laboratories.
Nanocopoeia was founded in 2001.
Nanocopoeia's headquarters is located in Saint Paul, MN, US.
Nanocopoeia's most recent funding round was for $500k (USD) in September 2006.
As of Sep 22, 2006, Nanocopoeia has disclosed funding of $500k (USD). Undisclosed round amounts are excluded.
Nanocopoeia has 31 employees as of Feb 4, 2024.
MAA Laboratories
